Cargando…
The cross-talk between PARylation and SUMOylation in C/EBPβ at K134 site participates in pathological cardiac hypertrophy
Poly(ADP-ribosyl)ation (PARylation) and SUMO modification (SUMOylation) are novel post-translational modifications (PTMs) mainly induced by PARP1 and SUMO1. Growing evidence has revealed that C/EBPβ plays multiple roles in biological processes and participates in cardiovascular diseases. However, th...
Autores principales: | Wang, Luping, Wang, Panxia, Xu, Suowen, Li, Zhuoming, Duan, Dayue Darrel, Ye, Jiantao, Li, Jingyan, Ding, Yanqing, Zhang, Wenqing, Lu, Jing, Liu, Peiqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741850/ https://www.ncbi.nlm.nih.gov/pubmed/35002525 http://dx.doi.org/10.7150/ijbs.65211 |
Ejemplares similares
-
Chrysophanol protects against doxorubicin-induced cardiotoxicity by suppressing cellular PARylation
por: Lu, Jing, et al.
Publicado: (2019) -
SIRT6 Suppresses NFATc4 Expression and Activation in Cardiomyocyte Hypertrophy
por: Li, Zhenzhen, et al.
Publicado: (2019) -
PRMT5 Prevents Cardiomyocyte Hypertrophy via Symmetric Dimethylating HoxA9 and Repressing HoxA9 Expression
por: Cai, Sidong, et al.
Publicado: (2020) -
SUMOylation and PARylation cooperate to recruit and stabilize SLX4 at DNA damage sites
por: González-Prieto, Román, et al.
Publicado: (2015) -
Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets
por: Krastev, Dragomir B., et al.
Publicado: (2018)